Updates are available Correction dated 2024-05-06
Click to view Correction: https://doi.org/10.1038/s41698-024-00587-w
-
Authors
Prosz, Aurel
Sahgal, Pranshu http://orcid.org/0000-0002-9857-3987
Huffman, Brandon M. http://orcid.org/0000-0002-0768-3145
Sztupinszki, Zsofia
Morris, Clare X.
Chen, David
Börcsök, Judit http://orcid.org/0000-0002-3290-3971
Diossy, Miklos
Tisza, Viktoria
Spisak, Sandor
Likasitwatanakul, Pornlada
Rusz, Orsolya
Csabai, Istvan http://orcid.org/0000-0001-9232-9898
Cecchini, Michael http://orcid.org/0000-0003-3504-0128
Baca, Yasmine
Elliott, Andrew
Enzinger, Peter
Singh, Harshabad
Ubellaker, Jessalyn
Lazaro, Jean-Bernard
Cleary, James M.
Szallasi, Zoltan
Sethi, Nilay S. http://orcid.org/0000-0002-3748-7559
- License Information
-
More Information
Article History
Received: 31 October 2023
Accepted: 22 February 2024
First Online: 8 April 2024
Change Date: 6 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41698-024-00587-w
Competing interests
: J.M. Cleary received research funding to his institution from Merus, Roche, and Bristol Myers Squibb. He received research funding from Merck, Astrazeneca, Arcus Biosciences, Apexigen, Esperas Pharma, Bayer, and Tesaro; received advisory board honorarium from Syros Pharmaceuticals and Blueprint Medicines. Z.S. is an inventor on a patent used in the myChoice HRD assay. N.S. Sethi is a consultant for Astrin Biosciences and Dewpoint.
